Skip to Content

NeuroPace Inc NPCE

Morningstar Rating
$14.00 +0.02 (0.14%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NPCE is trading at a 26% discount.
Price
$14.00
Fair Value
$43.22
Uncertainty
Very High
1-Star Price
$94.47
5-Star Price
$3.16
Economic Moat
Bwks
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NPCE is a good fit for your portfolio.

Trading Information

Previous Close Price
$13.98
Day Range
$13.6814.21
52-Week Range
$3.8018.15
Bid/Ask
$11.32 / $16.72
Market Cap
$396.82 Mil
Volume/Avg
126,312 / 111,008

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
171

Comparables

Valuation

Metric
NPCE
NARI
ANIK
Price/Earnings (Normalized)
407.50
Price/Book Value
18.864.711.79
Price/Sales
5.534.362.28
Price/Cash Flow
64.6936.80
Price/Earnings
NPCE
NARI
ANIK

Financial Strength

Metric
NPCE
NARI
ANIK
Quick Ratio
4.852.433.50
Current Ratio
5.713.095.26
Interest Coverage
−3.23−56.99
Quick Ratio
NPCE
NARI
ANIK

Profitability

Metric
NPCE
NARI
ANIK
Return on Assets (Normalized)
−21.61%5.07%−1.35%
Return on Equity (Normalized)
−94.96%6.37%−1.65%
Return on Invested Capital (Normalized)
−18.31%3.35%−2.24%
Return on Assets
NPCE
NARI
ANIK
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesPbblczdrXnqgjx$185.8 Bil
SYK
Stryker CorpMxvkvqkgstTdmh$124.7 Bil
MDT
Medtronic PLCFzcmtqsFjlrq$105.2 Bil
BSX
Boston Scientific CorpKvxsmgzhNhqrr$99.0 Bil
EW
Edwards Lifesciences CorpXvmjxgybsJkgzfv$52.3 Bil
DXCM
DexCom IncKcbtdwmjjPgnh$52.1 Bil
ZBH
Zimmer Biomet Holdings IncNsrfrtzrWxr$24.8 Bil
ALGN
Align Technology IncBwcthlrrkNtkqj$22.6 Bil
PHG
Koninklijke Philips NV ADRTjlfvxdgfWllgvm$18.5 Bil
PODD
Insulet CorpNysfbmxqqVwyhnm$11.5 Bil

Sponsor Center